About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, July 21st, 2014

The QualityStocks
Daily Stock List


Generex Biotechnology Corp. (GNBT)

OTCPicks, PennyTrader Publisher and Greenbackers reported previously on Generex Biotechnology Corp. (GNBT), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

OTCQB listed Generex Biotechnology Corp. engages in the research, development, and commercialization of drug delivery systems and technologies. It has developed a proprietary platform technology for the delivery of drugs into the human body via the oral cavity, with no deposit in the lungs. Its proprietary liquid formulations permits drugs normally administered through injection to undergo absorption into the body through the lining of the inner mouth using its proprietary RapidMist™ device. Its buccal insulin spray product is Generex Oral-lyn™. Antigen Express, Inc. is a wholly owned subsidiary of Generex Biotechnology.

Its RapidMist™ is an advanced buccal drug delivery technology. It consists of a proprietary formulation and a proprietary device design that can deliver drugs through the buccal mucosa safely. RapidMist™ has been shown to have a rapid onset of action with no lung deposition, precise dosage control, easy use and handling, and improved patient compliance.

Generex Biotechnology’s Generex Oral-lyn™ is an insulin spray for the treatment of Type I and Type II diabetes. Generex Oral-lyn™ is a safe, simple, fast, effective, and pain-free alternative to subcutaneous injections of prandial insulin. It is conveniently delivered to the membranes of the oral cavity by a straightforward asthma-like device with no pulmonary (lung) deposition. 

The Company’s subsidiary, Antigen Express, is a platform technology and product-based entity. The core platform technologies of Antigen consist of immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen is developing proprietary vaccine formulations for active immunotherapy and disease prevention. 

Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One technology focuses on modification of peptides with Ii-Key to increase potency. A second technology relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for strong stimulation of T-helper cells and prevents the further growth of cancer cells.

The Company's subsidiary, Antigen Express is developing the AE37 breast cancer vaccine. Generex Biotechnology recently announced two presentations demonstrating that certain patients with early stage breast cancer who receive AE37 may benefit in terms of reduced risk of relapse. The presentations were made at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which took place in Chicago from May 30 through June 3, 2014.

Generex Biotechnology Corp. (GNBT), closed Monday's trading session at $0.023, up 4.55%, on 2,501,380 volume with 101 trades. The average volume for the last 60 days is 2,852,411 and the stock's 52-week low/high is $0.02/$0.056.

Verde Science, Inc. (VRCI)

Vantage Wire, SmallCapVoice, PennyStocks24, PennyStock Tweets and WallstreetSurfers reported recently on Verde Science, Inc. (VRCI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Verde Science, Inc. plans to take an all-encompassing, integrated public health approach to medical marijuana. The Company is focusing on becoming the leader in providing services to legal, licensed cannabis cultivators and dispensaries and their patient community. Verde Science’s focus, in association with its partners, is on deploying an advanced variety of technical services to foster an integrated health care model in legal jurisdictions in North America. The Company’s shares trade on the OTC Markets’ OTCQB.

Verde does not want to own dispensaries. It wants to be a service provider to the dispensaries. The Company will provide capital for expansion and operation. Verde has state-of-the-art in growth technology as well as aeroponics. This will save the dispensaries substantial amounts of money and provide them with in house quality control.

Verde provides an array of products and services to its clients. The Company offers growers and their patient community premier, fully integrated, holistic health care products and programs.

Verde Science is one of the initial corporate players in the medical marijuana industry providing sophistication, controls, standards and innovation.

Recently, Verde Science announced that it signed its first long-term contract with Sherman Oaks Holistic Oasis (SOHO). SOHO is a legal, licensed medical marijuana dispensary located in Los Angeles County, California. SOHO services over 1,600 patients. Verde will earn an ongoing monthly management fee. It will be based on costs savings generated from its advisory services. Verde will also earn a royalty on all product sales.

In June, Verde Science announced the appointment of Mr. Bradley J. Dixon, J.D. to the Board of Directors. Mr. Dixon is a trial attorney and partner in the Boise, Idaho office of Stoel Rives, LLP. Stoel Rives has locations throughout the northwest and California. Mr. Dixon is ranked by Chambers and Partners. He was named in the 2013 Mountain States Directory of Super Lawyers. He has a broad spectrum of litigation experience. This includes Agricultural, Natural Resources, Labor and Employment, and Product Liability cases.

Verde Science, Inc. (VRCI), closed Monday's trading session at $0.027, down 12.90%, on 110,010 volume with 9 trades. The average volume for the last 60 days is 374,373 and the stock's 52-week low/high is $0.025/$0.094.

Liberty Star Uranium & Metals Corp. (LBSR)

PennyStocks24, Penny Stocks Finder, SuperStockTips, Stock Preacher, Beacon Equity Research, Penny Stock Craze, InvestorSoup, and TheMicrocapNews reported on Liberty Star Uranium & Metals Corp. (LBSR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, Liberty Star Uranium & Metals Corp. is a mineral exploration company engaged in the acquisition and exploration of mineral properties in Arizona and Alaska. Currently, the Company controls properties totaling approximately 26,011 acres located over what its Management considers some of North America’s richest mineralized areas for copper, gold, silver, molybdenum (moly), and uranium. Liberty Star Uranium & Metals is based in Tucson, Arizona. 

The Company’s projects include the Tombstone Super Project (TSP). This project initially consisted of 33 unpatented federal lode mining claims over a projected covered porphyry copper mineral center in southeast Arizona. In 2011 and 2012 more U.S. Bureau of Land Management (BLM) claims and Arizona Mining Exploration Permits were added. The Tombstone Super Project (TSP) hosts Liberty Star’s premier multi target property: Hay Mountain.

The Company maintains claims on two other claim blocks in Arizona: The East Silver Bell Porphyry Copper Project and the North Pipes Super Project. Additionally, via its wholly owned subsidiary, Big Chunk Corp., Liberty Star holds claims to the Big Chunk Super Project (BCSP) in Alaska.

Liberty Star announced in May that it signed a final settlement agreement and release of all claims on the Big Chunk Property, Alaska. It announced that a final settlement agreement and release of all claims was signed by Liberty Star and Northern Dynasty Minerals Ltd. including its subsidiary/affiliate U-5 Resources, Inc. Northern Dynasty releases Liberty Star from all claims.

In May, Liberty Star updated its shareholders and interested parties on the completion of the compilation and interpretation of the Hay Mountain porphyry copper geophysical data along with geochemistry and design of a Phase 1 drill program. During the last 6 months (from May) considerable additional details on the subsurface of the Hay Mountain porphyry copper geochemical anomaly have come to light.

Necessary capital funding for the Hay Mountain Project would be Phase 1 drilling at US$5 million to be used in the first year to confirm presence of ore grade mineralization. Post Phase 1 drilling activities of US$60 million are to be used over the next three years.

Last month, the Company announced that Phase 1 exploration drilling targets were selected at its Hay Mountain Project. Liberty Star’s intention is to permit these so that the drill can move around depending on results from drilled holes.

Liberty Star Uranium & Metals Corp. (LBSR), closed Monday's trading session at $0.0147, up 5.76%, on 1,367,306 volume with 34 trades. The average volume for the last 60 days is 1,365,353 and the stock's 52-week low/high is $0.0104/$0.041.

Manhattan Scientifics, Inc. (MHTX)

Hawk Associates reported recently on Manhattan Scientifics, Inc. (MHTX), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Manhattan Scientifics, Inc. concentrates on the commercialization of disruptive technologies in the nano-medicine space. At present, it is developing commercial medical prosthetics applications for its ultra-fine grain metals. Manhattan Scientifics’ intention is to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC - a unit of the Company. Manhattan Scientifics has offices in New Mexico, New York and Montreal.

The Company acquired the exclusive commercial rights (manufacturing and marketing) to Mr. Edward R. Flynn's (President and CEO of Senior Scientific, LLC) patents and Intellectual Property (IP) in the emerging field of nano medicine; precisely, Dr. Flynn's work in biomagnetic detection of cancer and other diseases by way of magnetic field sensors.

The Company builds IP portfolios and business cases supporting new technologies. It guides them to relationships with industrial partners who are well-prepared to launch product. Accordingly, the lab and inventor see the technology enter the marketplace. The industrial partner gets a solid foundation for a new product. Manhattan Scientifics profits from building the licensing bridge to industry.
At present, Manhattan Scientifics is focusing on nanostructured metals technology through wholly-owned subsidiary Metallicum, Inc.  In addition, it is centering on nanoparticle based cancer detection through wholly owned subsidiary Senior Scientific, LLC.  Additionally, it is working on the commencement of product trials on its cancer detection product, scheduled for this year.

The nanostructured metals technology has been revenue producing for several years. The cancer detection technology can detect cancer years earlier. Manhattan Scientifics has expertise in licensing from the national laboratories (the Los Alamos National Laboratory (LANL) and the Sandia National Laboratory (SNL)) and in working with individual inventors.

Manhattan Scientifics announced in January that it executed an agreement to collaborate with The University of Texas MD Anderson Cancer Center (MDACC) to advance, demonstrate and validate a breakthrough technology developed by Edward R. Flynn, PhD, for the very early detection of cancer. Manhattan Scientifics recently announced that it delivered its break-through cancer measurement instrument to The University of Texas M.D. Anderson Cancer Center.

In March, Manhattan Scientifics announced a collaboration with Azano Biotech that will make NanoMRX Precision Nanoparticles available for purchase. The nanoparticles are manufactured by Senior Scientific chiefly to support Senior Scientific’s NanoMRX cancer detection technology. NanoMRX nanoparticles are uniquely precise and reproducible for consistent results. This is the first time they will be made available for use outside of Senior Scientific’s own programs.

On May 22, 2014, Manhattan Scientifics announced that it completed the testing phase of its MRX II™ cancer screening instrument. The Company expects pre-clinical trials to start at some point this year.

Manhattan Scientifics, Inc. (MHTX), closed Monday's trading session at $0.135, up 2.27%, on 34,246 volume with 15 trades. The average volume for the last 60 days is 505,270 and the stock's 52-week low/high is $0.031/$0.1795.

Cocrystal Pharma, Inc. (COCP)

PennyStocks Forever reported recently on Cocrystal Pharma, Inc. (COCP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Based in Bothell, Washington, Cocrystal Pharma, Inc. is a biotechnology company developing new antiviral therapeutics for human diseases. On April 16, 2014, Cocrystal Pharma announced that, effective April 15, 2014, its stock began trading under the new symbol "COCP". The updated stock trading symbol marks the successful completion of its recent merger with Biozone Pharmaceuticals, Inc., as announced on January 3, 2014. Cocrystal Pharma lists on the OTC Markets’ OTCQB.

The Company focuses on the discovery and development of novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. Cocrystal Pharma employs unique technologies and Nobel Prize winning expertise to create first- and best-in-class antivirals. The design of these technologies and its market-focused approach to drug discovery are to efficiently deliver small molecule therapeutics that are safe, effective, and convenient to administer.

Cocrystal Pharma now has five therapeutic programs targeting the Hepatitis C Virus (HCV), Influenza Virus, the Human Rhinovirus (HRV), Dengue Virus, and the Norovirus. It is targeting two Hepatitis C replication enzymes with its Polymerase program at lead optimization stage and its Helicase program at lead identification stage. Its Influenza, HRV, Dengue, and Norovirus programs are targeting unmet multi-billion dollar market opportunities with first-in-class antivirals. 

The Company is developing drug candidates specifically designed to be effective against all strains of the influenza virus and to have a high barrier to resistance. Selection of a lead compound for clinical development is planned to take place by early 2015. Regulatory filings to begin clinical studies for influenza are planned for December 2015.

Recently, Cocrystal Pharma reported results for the first quarter ended March 31, 2014. Highlights of its business include that on January 27 the Company raised $2,750,000 from eight accredited investors including OPKO Health (OPK). OPKO Health Chairman/CEO, Dr. Phillip Frost, is Cocrystal’s largest shareholder. Proceeds from the financing will be used for Research and Development (R&D) and general working capital. Cocrystal Pharma’s cash and equivalents and marketable securities as of March 31, 2014 were $9,884,000.

Furthermore, its Hep C project continued to progress with the selection of a lead candidate to take forward into clinical trials. Cocrystal Pharma anticipates filing an IND, or its equivalent in another country, this December.

Cocrystal Pharma, Inc. (COCP), closed Monday's trading session at $0.314, up 2.95%, on 659,186 volume with 230 trades. The average volume for the last 60 days is 273,948 and the stock's 52-week low/high is $0.2111/$0.97.


The QualityStocks
Company Corner


Oriens Travel and Hotel Management Corp. (OTHM)

The QualityStocks Daily Newsletter would like to spotlight Oriens Travel and Hotel Management Corp. (OTHM). Today, Oriens Travel and Hotel Management Corp. closed trading at $0.0004, even with yesterday's close, on 3,495,743 volume with 10 trades. The stock’s average daily volume over the past 60 days is 23,276,384, and its 52-week low/high is $0.0003/$0.0024.

Oriens Travel and Hotel Management Corp. (OTHM) is a provider of proprietary technology, marketing solutions, infrastructure and branding services to hotel operators.

The company's innovative platform functions as a powerful vehicle to help hotel operators achieve greater success in three specific areas: (i) expanded international exposure and recognition, (ii) powerful core structure, and (iii) high occupancy rates that drive increases in bottom-line profits. Oriens continuously refines its suite of proprietary solutions to deliver measurable and proven results to hotel properties. This success has been reflected in those properties operating under the Hotel PURE brand as well as with independent boutique hotel properties utilizing the company's Friendly Reservation Online (FROL) booking engine technology and internet marketing services.

Operating a successful bi-lateral business model, Oriens has four objectives:

    • To franchise the Hotel PURE brand to selected hotel properties worldwide similar to the business model currently employed by Big Brand operators such as Holiday Inn, Marriott, Sheraton and others;

    • Provide highly efficient and economical back-end booking engine technology services to independently branded boutique hotels that require a robust online presence;

    • Launch a stand-alone online hotel booking search engine primarily focused on Central America; and,

    • Expand the portfolio of Oriens-owned boutique hotels operating under the Hotel PURE brand.

The company initially began growing its operations primarily in the United States. However most recently, major opportunities in Central America began presenting themselves, giving Oriens the ability to retool its business model. Now the company is positioned to acquire, own and operate its own properties – which would be marketed under the new brand with occupancies handled by the re-launched online booking engine system.

Ultimately, Oriens intends to become a top-tier hotel brand operator and Internet booking and marketing service provider, qualifying as a preferred supplier to lending institutions. The company also intends to establish an invaluable international footprint with its online booking engine technology and marketing offerings; making that segment of its business a prime acquisition target for major online travel search and booking engine companies. Advancement toward this goal is guided by an executive management team with deep expertise in technology, banking, management, hospitality, branding and marketing, technical development and more. Disclaimer

Oriens Travel and Hotel Management Corp. Company Blog

Oriens Travel and Hotel Management Corp. News:

Oriens Travel and Hotel Management Corp. to Obtain Traditional Financing Facilitating Acquisitions

Oriens Set to Finalize First Acquisition; Subsidiary Incorporated to Complete Purchase & Asset Transfer

Oriens Provides Recap Following Shareholder Update

Mobile Lads Corp. (MOBO)

The QualityStocks Daily Newsletter would like to spotlight Mobile Lads Corp. (MOBO). Today, Mobile Lads Corp. closed trading at $0.33, up 13.79%, on 13,290 volume with 14 trades. The stock’s average daily volume over the past 60 days is 9,545, and its 52-week low/high is $0.15/$0.33.

Mobile Lads Corp. today announced the signing of a Joint Venture and Reseller Agreement with Smart Mobile Rewards. covering Mobile Lads' suite of mobile authentication and payment products. In addition, Mobile Lads and Smart Mobile Rewards will jointly develop authentication products to allow the creation and implementation of more sophisticated and higher value voucher and loyalty products.

Mobile Lads Corp. (MOBO) designs and delivers secure, wide-area wireless transaction software solutions for the consumer finance, web and health payment processing sectors. The company’s solutions provide streamlined, continuous access to time-sensitive information and data on multiple network standards. Mobile Lads’ products and services, offered through its Xtreme Mobility division, centers on three core technologies that simplify and secure wireless communications: xmVerify, xmBilling, and xmOne.

xmVerify is a real-time mobile transaction security service that prevents credit card fraud by giving users control over the authorization process when making purchases. Using one of the best cryptographic services, and in compliance with most all available platforms, xmVerify sends a transaction authorization request directly to the user’s mobile phone to ensure authenticity.

xmBilling is a mobile platform that provides customers with a convenient and secure way to review and authorize automatic billing transactions, easing the challenges of automated and volume-based billing. The system sends the user a text message with a URL leading to an online e-bill where they can review details of the bill and authorize the payment via credit card with the use of their PIN number.

The xmOne mobile platform provides an array of encrypted mobile services, including top-up, payment processing, emergency notification and marketing, ideal for students and higher education facilities. xmOne interfaces with a school’s existing campus card account system to enable students to perform a variety of banking transactions from their cell phones. The university or college benefits from increased usage of the flex-dollar ecosystem, reduces overhead from ADMs, and can be customized to each school’s individual brand.

Mobile Lads is guided by a management team with a unique blend of in-depth technical expertise in wireless channel communications and a solid background in business strategy and consumer analysis. The company’s vision is to grow as a leading-edge wireless solution provider by enabling innovative, wide-area communication solutions on a global scale. Disclaimer

Mobile Lads Corp. Company Blog

Mobile Lads Corp. News:

Mobile Lads Signs Reseller Agreement With Smart Mobile Rewards

Mobile Lads Signs Letter of Intent for Xtreme Mobility Software Acquisition

Mobile Lads Corp. (MOBO) is “One to Watch”

Innocent, Inc. (INCT)

The QualityStocks Daily Newsletter would like to spotlight Innocent, Inc. (INCT). Today, Innocent, Inc. closed trading at $0.0435, up 11.54%, on 259,200 volume with 44 trades. The stock’s average daily volume over the past 60 days is 31,019, and its 52-week low/high is $0.0005/$0.095.

Innocent, Inc. was pleased to announce today that it has appointed Peter Kent as a member of the Company's advisory council. Peter has extensive familiarity across the spectrum of governance, business and legal responsibilities and has conducted high-level negotiations leading to transactions with large corporations including Chevron, Texaco (USA), Mitsubishi Kasei (Tokyo), Hoganas (Sweden), Imperial Oil (Canada) and others.

Innocent, Inc. (INCT) is a development stage oil and gas exploration and production company focused on developing properties in North America. The company plans to minimize the risk of exploration through development of proved petroleum reserves, and expects to maximize profit through strategic acquisition and liquidation of selected oil and gas properties.

The company specializes in acquiring low risk, high upside properties with substantial exploration potential. Through improvements in oil and gas production technologies, Innocent aims to rapidly increase production levels and generate predictable, sustainable value. The business strategy utilized calls for both 100% acquisitions and joint-ventures to maximize production capacity.

Evergreen Petroleum, a joint venture partner, is working closely with the company to explore oil-bearing formations in Wyoming. Evergreen has conducted and will continue to conduct both regional and local geological studies to define prospects that are worthy of acquiring oil and gas leases. By partnering with industry experts such as Evergreen, Innocent has strategically added extensive technical guidance and field management experience.

Even during challenging times, the world depends on oil & gas exploration and production companies to deliver millions of barrels of oil every day. Increased demand from emerging countries such as China further escalates competition for this precious resource. Backed by an experienced group of professionals, Innocent is well positioned to generate substantial revenues in the short and long term future. Disclaimer

Innocent, Inc. Company Blog

Innocent, Inc. News:

Innocent Inc. Appoints Peter Kent to Advisory Council

Innocent Inc. Appoints Denis Clement to Advisory Council

Innocent Inc. Launches Advisory Council

Great Plains Holding, Inc. (GTPH)

The QualityStocks Daily Newsletter would like to spotlight Great Plains Holding, Inc. (GTPH). Today, Great Plains Holding, Inc. closed trading at $1.28, even for the day. The stock’s average daily volume over the past 60 days is 184, and its 52-week low/high is $0.85/$2.00.

Great Plains Holding, Inc. (GTPH) operates through two wholly owned subsidiaries: Ashland Holdings, LLC, focused on the real estate sector; and LiL Marc, Inc., maker of the "LiL Marc" training urinal for toddler boys. This diversification model enables Great Plains to achieve multiple revenue streams and consistently increase hard assets.

Ashland Holdings, LLC is engaged in the acquisition and operation of commercial real estate, including, but not limited to, self-storage facilities, apartment buildings, manufactured housing communities for senior citizens, and other income-producing properties. The subsidiary’s current portfolio includes a 1,400-square-foot corporate office building; an 800-square-foot warehouse for LiL Marc operations; and two adjacent parcels of land, one of which includes a manufactured home that is rented out for additional income. Ashland and LiL Marc plan to occupy one or more of the five office spaces located in the corporate office building to accommodate expected expansion. The remaining vacant offices may be leased to tenants to create a source of revenue.

LiL Marc, Inc. is Great Plains’ principal business activity. Founded in 1999, the subsidiary engages in the manufacturing and marketing of training urinals for boys in the United States. The LiL Marc boys potty training urinal looks like the full sized urinals found in public restrooms, but are manufactured on a smaller scale in proportion to the smaller size of toddlers in training. In conjunction with the roll-out of an aggressive marketing campaign for the LiL Marc product, Great Plains’ management team is building a client list of retailers with brick and mortar stores and other consumer outlets to participate in the broader retail market. With advertising strategies in place, management envisions growth and widespread distribution of the LiL Marc training urinal.

Great Plains also intends to purchase privately-owned profitable businesses owned by baby boomers looking to retire. As the company continues to execute its expansion strategy and add additional subsidiaries, all potential purchases will be reviewed by management to ensure they meet very stringent requirements. Disclaimer

Great Plains Holding, Inc. Company Blog

Great Plains Holding, Inc. News:

Great Plains Holdings, Inc. President, COO Featured in Exclusive QualityStocks Interview

Great Plains Holdings, Inc. Completes Final Phase of Real Estate Asset Project Ahead of Schedule

Great Plains Holdings, Inc. Partners With TexStar Energy for Texas Lease With Nearly 3M Barrels of Estimated Oil Reserves

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.64, even for the day. The stock’s average daily volume over the past 60 days is 5,105, and its 52-week low/high is $0.25/$0.89.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve.  According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months.  VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits.  In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations. 

AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data.  To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Receives Notice of Allowance for Canadian Patent Expanding Stem Cell Technology Platform

VistaGen Joins HESI's Cardiac Safety Committee and Working Groups

VistaGen Receives Notice of Allowance for U.S. Patent Expanding Stem Cell Technology Platform for Drug Rescue and Regenerative Medicine


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Real Pennies




Wall Street Resources

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251